E Magnus Ohman Selected Research

Unstable Angina

10/2021	Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry.
1/2020	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
5/2017	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
1/2017	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
8/2013	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
11/2012	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
10/2012	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
12/2010	Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative.
7/2010	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
3/2010	Influence of clinical trial participation on subsequent antithrombin use.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E Magnus Ohman Research Topics

Disease

121	Acute Coronary Syndrome 01/2022 - 01/2002
88	Hemorrhage 09/2022 - 05/2004
86	Myocardial Infarction 01/2022 - 02/2002
44	ST Elevation Myocardial Infarction 01/2022 - 08/2002
36	Stroke (Strokes) 03/2022 - 05/2004
30	Unstable Angina 10/2021 - 08/2002
27	Heart Failure 10/2020 - 01/2002
25	Thrombosis (Thrombus) 10/2021 - 01/2001
19	Cardiogenic Shock 01/2022 - 08/2003
19	Infarction (Infarctions) 01/2022 - 02/2002
18	Ischemia 11/2021 - 06/2002
16	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2002
16	Non-ST Elevated Myocardial Infarction 05/2017 - 08/2003
12	Diabetes Mellitus 09/2022 - 06/2002
12	Thrombocytopenia (Thrombopenia) 12/2012 - 02/2005
11	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 01/2001
9	Hypertension (High Blood Pressure) 12/2017 - 01/2002
8	Chronic Renal Insufficiency 09/2022 - 03/2006
7	Myocardial Ischemia (Ischemic Heart Diseases) 03/2015 - 01/2002
7	Chest Pain (Chest Pains) 04/2008 - 01/2001
6	Atrial Fibrillation 01/2019 - 09/2003
6	Vascular Diseases (Vascular Disease) 01/2019 - 10/2009
5	Renal Insufficiency (Renal Failure) 12/2017 - 09/2006
5	Pathologic Constriction (Stenosis) 12/2017 - 06/2014
5	Necrosis 03/2008 - 01/2001
4	Hypercholesterolemia 02/2016 - 04/2006
4	Atherosclerosis 08/2013 - 03/2008
3	Shock 01/2019 - 09/2011
3	Heart Diseases (Heart Disease) 11/2015 - 01/2001
3	Peripheral Arterial Disease 11/2014 - 08/2013
3	Ischemic Stroke 01/2014 - 09/2004
3	Body Weight (Weight, Body) 08/2013 - 06/2009
2	Neoplasms (Cancer) 01/2016 - 01/2016
2	Transient Ischemic Attack 06/2015 - 12/2006
2	Death (Near-Death Experience) 01/2015 - 12/2009

Drug/Important Bio-Agent (IBA)

38	Heparin (Liquaemin)FDA LinkGeneric 12/2014 - 09/2004
34	Clopidogrel (Plavix)FDA Link 01/2020 - 04/2006
31	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2022 - 06/2002
30	Glycoproteins (Glycoprotein)IBA 03/2015 - 05/2004
24	bivalirudin (Angiomax)FDA Link 12/2014 - 09/2004
23	Prasugrel Hydrochloride FDA Link 01/2020 - 07/2010
17	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2001
17	TroponinIBA 04/2017 - 01/2001
15	TicagrelorIBA 09/2022 - 12/2016
13	Platelet Membrane Glycoprotein IIbIBA 12/2010 - 12/2002
11	AntithrombinsIBA 12/2012 - 02/2005
10	Eptifibatide (Integrilin)FDA Link 07/2010 - 02/2002
10	Enoxaparin (Lovenox)FDA LinkGeneric 03/2010 - 06/2004
9	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 01/2006
8	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 03/2022 - 01/2016
8	Fibrinolytic Agents (Antithrombotic Agents)IBA 08/2017 - 05/2004
8	Pharmaceutical PreparationsIBA 01/2016 - 09/2002
7	CreatinineIBA 04/2017 - 06/2002
7	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 08/2013 - 03/2004
7	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 06/2010 - 05/2004
6	AnticoagulantsIBA 01/2022 - 09/2007
5	omega-Chloroacetophenone (Mace)IBA 01/2022 - 10/2015
5	Troponin T (Troponin T1)IBA 01/2017 - 06/2002
5	MB Form Creatine KinaseIBA 04/2007 - 04/2003
5	Platelet Membrane GlycoproteinsIBA 02/2007 - 08/2002
5	Creatine Kinase (Creatine Phosphokinase)IBA 01/2006 - 01/2001
4	apixabanIBA 01/2022 - 01/2016
4	RivaroxabanIBA 01/2019 - 05/2017
4	Abciximab (ReoPro)FDA Link 07/2010 - 09/2002
4	ORALIT (ORS)IBA 05/2009 - 09/2006
4	Tissue Plasminogen Activator (Alteplase)FDA Link 10/2007 - 02/2002
3	Thrombin Receptors (Thrombin Receptor)IBA 01/2022 - 01/2016
3	Warfarin (Coumadin)FDA LinkGeneric 01/2019 - 02/2008
3	Glucose (Dextrose)FDA LinkGeneric 05/2017 - 01/2006
3	Hemoglobins (Hemoglobin)IBA 04/2017 - 02/2009
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 03/2015 - 11/2014
3	Troponin IIBA 11/2007 - 04/2003
3	Tenecteplase FDA Link 07/2005 - 09/2004
3	Tirofiban (Aggrastat)FDA Link 07/2005 - 09/2002
3	paragonIBA 04/2003 - 08/2002
2	Mineralocorticoid Receptor AntagonistsIBA 10/2020 - 02/2014
2	Purinergic P2Y Receptor AntagonistsIBA 08/2020 - 12/2016
2	pro-brain natriuretic peptide (1-76)IBA 10/2019 - 07/2017
2	MicroRNAs (MicroRNA)IBA 10/2019 - 01/2017
2	Cytochrome P-450 CYP2C19IBA 01/2019 - 03/2016
2	C-Reactive ProteinIBA 07/2017 - 02/2011
2	Ranolazine FDA Link 05/2017 - 01/2016
2	Antihypertensive Agents (Antihypertensives)IBA 08/2013 - 04/2013

Therapy/Procedure

98	Therapeutics 03/2022 - 07/2002
85	Percutaneous Coronary Intervention 09/2022 - 09/2002
28	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/2021 - 05/2004
14	Stents 01/2020 - 08/2003
10	Thrombolytic Therapy 09/2008 - 02/2002
9	Drug-Eluting Stents 03/2022 - 06/2003
9	Counterpulsation (External Counterpulsation) 01/2019 - 06/2003
7	Secondary Prevention 08/2017 - 08/2003
5	Catheters 01/2022 - 06/2002
5	Blood Transfusion (Blood Transfusions) 06/2015 - 10/2005
5	Contraindications 05/2010 - 05/2007
4	Heart-Assist Devices 01/2022 - 01/2015
4	Patient Readmission 01/2015 - 10/2009
4	Erythrocyte Transfusion 05/2009 - 03/2005
3	Drug Therapy (Chemotherapy) 02/2014 - 02/2009
3	Length of Stay 11/2008 - 12/2005
2	Surgical Amputation (Amputations) 11/2014 - 07/2009